Piperazine, 1-diphenylmethyl-4-methyl-, dihydrochloride

Piperazine, 1-diphenylmethyl-4-methyl-, dihydrochloride Chemische Eigenschaften,Einsatz,Produktion Methoden

• Biologische Aktivität

  Cyclizine 2HCl is a piperazine derivative with Histamine H1 receptor antagonist activity.

• in vitro

  Cyclizine is a piperazine histamine H1 receptor antagonist and has anticholinergic and antiemetic properties. It increases lower esophageal sphincter tone and reduces the sensitivity of tortuous organs.

• in vivo

  Cyclizine is metabolized to its N-desmethyl derivative, Norcyclizine, which has little antihistamine (H1) activity compared to Cyclizine. After oral administration of Cyclizine, the effect will be produced within 30 minutes, and the maximum effect will be achieved within 1-2 hours, which can last for 4-6 hours. Cyclizine administered orally at a dose of 50 mg alone in healthy adult volunteers produced peak plasma concentrations of approximately 70 ng/mL two hours after dosing. The plasma elimination half-life is about 20 hours.

• target

  Target	Value
  Histamine H1 receptor

Piperazine, 1-diphenylmethyl-4-methyl-, dihydrochloride Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(36)Suppliers

5897-18-7, Piperazine, 1-diphenylmethyl-4-methyl-, dihydrochloride Verwandte Suche: